Soft Tissue Sarcoma with Jonathan C. Trent, MD, PhD and Shreyaskumar R. Patel, MD: Case 2 - Episode 10
How has the recent approval of trabectedin influenced treatment options for patients such as Michael?
The recent approval of trabectedin for patients with metastatic or advanced liposarcoma and leiomyosarcoma has been a tremendous breakthrough. The patient in the case that we just discussed has a metastatic mixoid liposarcoma. These patients’ tumors can regress often briskly with standard chemotherapy such as an anthracycline and ifosfamide. However, these tumors will eventually become resistant to standard therapies.
The approval of trabectedin for the treatment of patients with mixoid liposarcoma has been a tremendous breakthrough. This is based on a phase III study that compared trabectedin, 1.5 mg/m2
CASE: Soft-Tissue Sarcoma Case 2
Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.
In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.